NSE filing, NSE: EMAPARTNER. Summary written from the filing by ALFA Finder's alert engine.
EMA Partners India Ltd: key numbers
- Share price
- ₹89.05
- Market cap
- ₹207.0 Cr
- Revenue (annual)
- ₹87.36 Cr
- Net profit (annual)
- ₹12.31 Cr
- P/E (TTM)
- 16.8×Sector 45.0×
- Promoter holding
- 65.76%
- FII holding
- 0.12%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from EMA Partners India Ltd
All →EMA Partners India H1 FY27 Results: Net Profit ₹9 Cr, Up 26.8% YoY
EMA Partners India Ltd reported revenue from operations of ₹83.9 Cr (+107.2% YoY) and net profit of ₹9 Cr (+26.8% YoY) for H1 FY27.
- Key figure
- Net profit ₹9 Cr · +26.8% YoY
EMA Partners India Other Announcement
EMA Partners India Limited filed its Regulation 74(5) certificate for the quarter ended September 30, 2026, confirming no rematerialisation requests were received.
EMA Partners India Partnership
EMA Partners India Limited has entered a strategic partnership with STAIR Digital to launch EMA STAIR Board Services. The collaboration focuses on board governance, strategy, and AI-driven advisory.
EMA Partners India Annual General Meeting
EMA Partners India Limited held its 23rd Annual General Meeting on September 28, 2026, via video conference, discussing financial statements and director appointments.
EMA Partners India Merger & Restructuring
EMA Partners India Limited is merging three of its wholly owned subsidiaries into itself. No consideration is payable for this internal restructuring.
EMA Partners India Acquisition
EMA Partners India Limited announced a fast-track merger of its wholly-owned subsidiaries, EMA Partners Executive Search, Emagine People Technologies, and EMA Decision Dynamics, with itself.
Other other announcement announcements
All →Kansai Nerolac Paints Other Announcement
Kansai Nerolac authorised Pravin Chaudhari, Yash Ahuja and Rukmini Subramanian to determine material events from 1 December 2026. It only lists KMP and contact details.
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.
Physicswallah Other Announcement
Physicswallah's IPO monitoring report flags a deviation from offer objects for the quarter ended September 30, 2026. The diverted funds were restored on October 30, 2026.
Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
PDS Other Announcement
PDS Limited submitted the CRISIL Ratings monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation in the utilisation of its QIP proceeds.